Back to today’s briefing

Story perspectives

FDA Targets Telehealth Firms Over Misleading Drug Claims

3/4/2026

37 4 Full Breakdown

Summary

Story summary

The FDA issued 30 warning letters to telehealth companies for misleading claims about compounded GLP-1 drugs.
This marks the second wave of enforcement, following a crackdown begun last September.
FDA Commissioner Marty Makary said compounded drugs meet patient needs but must respect FDA review.
Hims & Hers has been referred to the Department of Justice for potential criminal violations tied to these practices.

1 of 1

Story summary

The FDA issued 30 warning letters to telehealth companies for misleading claims about compounded GLP-1 drugs.
This marks the second wave of enforcement, following a crackdown begun last September.
FDA Commissioner Marty Makary said compounded drugs meet patient needs but must respect FDA review.
Hims & Hers has been referred to the Department of Justice for potential criminal violations tied to these practices.